Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. David Meek bought Bluebird Bio last year ...

Many blood cancers can be treated with a potentially curative stem cell transplant, but this procedure introduces a serious complication risk that can become deadly. A new type of cell therapy gives ...

The approval of Tregzi—the first regulatory greenlight for Orca Bio—was based on a Phase 3 study in which patients on the therapy were twice as likely to survive without cancer relapse and without ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Orca Bio's manufacturing facility in Sacramento, California. Orca Bio has become a commercial-stage company with the FDA approval of Tregzi, a cell-based immunotherapy designed to prevent graft-versus ...

Orca Bio has jumped into the commercial market with FDA approval for Tregzi, a first-of-its-kind engineered cell therapy for blood cancer patients requiring transplants. Tuesday, the FDA approved the ...

Electromagnetic network-targeted field (ENTF) brain stimulation therapy is a promising approach to reduce poststroke disability. Two pilot, randomized, sham-controlled trials showed safety and signals ...

Add Yahoo as a preferred source to see more of our stories on Google. Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020.

June 30 (Reuters) - The U.S. Food and Drug Administration said on Tuesday it has approved Orca Bio's therapy for the treatment of ‌certain blood cancers, which also aims to lower the risk of stem cell ...

Orca Bio’s TREGZI™ Receives U.S. FDA Approval as First and Only Precision-Engineered Cell Therapy for Allogeneic Transplant in Adults with Hematological Malignancies The approval of TREGZI, clinically ...

The company is “especially excited” about an immune cell therapy manufacturing technology included in the deal, a Merck KGaA executive said. Merck KGaA has agreed to buy Bio-Techne for $11.3 billion ...

Remix Therapeutics is going public via a reverse merger with Passage Bio, a gene therapy company co-founded by Jim Wilson that, while once worth more than $1 billion, has seen its stock price plummet ...